Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe
Among the wealth of emerging targets in oncology, immune system suppressing regulatory T cells — better known as “Tregs” — have earned some big-name interest in recent years. Now, a West Coast startup mapping Tregs in human tissue has scored a slate of Big Pharma backers to drive its growing pipeline into the clinic.
South San Francisco-based TRexBio emerged from stealth Tuesday with a $59 million Series A and the backing of investment funds from Big Pharma giants Eli Lilly, J&J and Pfizer, the biotech said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.